Vedolizumab in patients with concurrent primary sclerosing cholangitis and inflammatory bowel disease does not improve liver biochemistry but is safe and effective for the bowel disease
| Image |  |
|---|---|
| Description | scientific article |
| Author/s |
author: Britt Christensen Joel Pekow |
| Publication date | January 29, 2018 |
| Language | English |
| Country of origin | |
| Wikipedia link | |
| Copyright status | |
| Missing/wrong data? | Edit Wikidata item |